| Combination of | |
|---|---|
| Darunavir | HIV protease inhibitor |
| Cobicistat | Cytochrome P450 (CYP3A) inhibitor |
| Clinical data | |
| Trade names | Rezolsta, Prezcobix |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C67H90N10O12S3 |
| Molar mass | 1323.70 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Darunavir/cobicistat, sold under the brand names Prezcobix (US) and Rezolsta (EU), is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS. [3] It contains darunavir and cobicistat. [3] [5] [6] Darunavir is an HIV protease inhibitor and cobicistat increases the effectiveness of darunavir by blocking its metabolism by the enzyme CYP3A. [6] [3]
Darunavir/cobicistat was approved for use in the European Union in November 2014, and for use in the United States in January 2015. [4] [7] [8] [3] [9]